ダウンロード数: 183
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
899741.pdf | 225.05 kB | Adobe PDF | 見る/開く |
タイトル: | Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy |
著者: | Koshiyama, Masafumi Matsumura, Noriomi Imai, Saeko Yamanoi, Koji Abiko, Kaoru Yoshioka, Yumiko Yamaguchi, Ken Hamanishi, Junzo https://orcid.org/0000-0002-7750-0623 (unconfirmed) Baba, Tsukasa Konishi, Ikuo |
著者名の別形: | 越山, 雅文 松村, 謙臣 山ノ井, 康二 安彦, 郁 吉岡, 弓子 山口, 建 濱西, 潤三 馬場, 長 小西, 郁生 |
発行日: | 15-Feb-2017 |
出版者: | International Scientific Literature |
誌名: | Medical Science Monitor |
巻: | 23 |
開始ページ: | 826 |
終了ページ: | 833 |
抄録: | BACKGROUND: The aim of this study was to evaluate the antiemetic effect of aprepitant and to determine how to provide triple combination therapy (aprepitant/azasetron/dexamethasone) to women receiving paclitaxel/carboplatin moderately emetogenic chemotherapy (MEC). MATERIAL AND METHODS: The current study was a prospective study of 163 women with gynecologic cancers. We compared the digestive symptoms scores (nausea, vomiting, appetite loss, and dietary intake) of 37 women with ovarian cancers before and after aprepitant administration. We also compared these symptoms in women who underwent 193 cycles of triple combination therapy with symptoms of women who underwent 226 cycles of double combination therapy. For triple combination therapy, azasetron, dexamethasone (reduced dose: 40% of 20 mg), and aprepitant (125 mg) were administered on Day 1, followed by only aprepitant (80 mg) administration on Days 2 and Day 3. RESULTS: In 37 women with ovarian cancer, three symptoms, nausea, appetite loss, and dietary intake, were significantly improved by primarily adding aprepitant to double combination therapy in the delayed phase of MEC. Upon comparing their digestive symptoms in all cycles, however, these three symptoms were not significantly different in the delayed phase. Furthermore, all four symptoms in all cycles were worse following triple combination therapy than following double combination therapy in the acute phase (p<0.02). The control of digestive symptoms was generally insufficient without the administration of dexamethasone. CONCLUSIONS: Primary aprepitant as an addition to MEC demonstrated efficacy in improving digestive symptoms in the delayed phase. However, its effect may decrease with repeated use. To improve the antiemetic effect, the dose reduction of dexamethasone should be restricted on Day 1 and dexamethasone should be used throughout the delayed phase as well. |
著作権等: | This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. |
URI: | http://hdl.handle.net/2433/218692 |
DOI(出版社版): | 10.12659/MSM.899741 |
PubMed ID: | 28198358 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。